ID   ZN268_HUMAN             Reviewed;         947 AA.
AC   Q14587; Q8TDG8; Q96RH4; Q9BZJ9;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   29-AUG-2001, sequence version 2.
DT   28-JUN-2023, entry version 211.
DE   RecName: Full=Zinc finger protein 268;
DE   AltName: Full=Zinc finger protein HZF3;
GN   Name=ZNF268;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Embryo;
RX   PubMed=11311945; DOI=10.1016/s0167-4781(01)00194-4;
RA   Gou D.M., Sun Y., Gao L., Chow L.M.C., Huang J., Feng Y.D., Jiang D.H.,
RA   Li W.X.;
RT   "Cloning and characterization of a novel Kruppel-like zinc finger gene,
RT   ZNF268, expressed in early human embryo.";
RL   Biochim. Biophys. Acta 1518:306-310(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY.
RX   PubMed=12200376; DOI=10.1182/blood-2002-02-0513;
RA   Krackhardt A.M., Witzens M., Harig S., Hodi F.S., Zauls A.J., Chessia M.,
RA   Barrett P., Gribben J.G.;
RT   "Identification of tumor-associated antigens in chronic lymphocytic
RT   leukemia by SEREX.";
RL   Blood 100:2123-2131(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3; 4; 5; 6 AND 7), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=16865230;
RA   Shao H., Zhu C., Zhao Z., Guo M., Qiu H., Liu H., Wang D., Xue L., Gao L.,
RA   Sun C., Li W.;
RT   "KRAB-containing zinc finger gene ZNF268 encodes multiple alternatively
RT   spliced isoforms that contain transcription regulatory domains.";
RL   Int. J. Mol. Med. 18:457-463(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3; 4; 5; 6 AND 7), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=18949428;
RA   Zhao Z., Wang D., Zhu C., Shao H., Sun C., Qiu H., Xue L., Xu J., Guo M.,
RA   Li W.;
RT   "Aberrant alternative splicing of human zinc finger gene ZNF268 in human
RT   hematological malignancy.";
RL   Oncol. Rep. 20:1243-1248(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 549-947.
RX   PubMed=7865130; DOI=10.1089/dna.1995.14.125;
RA   Abrink M., Aveskogh M., Hellman L.;
RT   "Isolation of cDNA clones for 42 different Kruppel-related zinc finger
RT   proteins expressed in the human monoblast cell line U-937.";
RL   DNA Cell Biol. 14:125-136(1995).
RN   [7]
RP   FUNCTION (ISOFORM 1), AND SUBCELLULAR LOCATION.
RX   PubMed=12822888; DOI=10.1080/1521654031000110208;
RA   Sun Y., Gou D.M., Liu H., Peng X., Li W.X.;
RT   "The KRAB domain of zinc finger gene ZNF268: a potential transcriptional
RT   repressor.";
RL   IUBMB Life 55:127-131(2003).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.
RX   PubMed=15547661;
RA   Sun Y., Shao H., Li Z., Liu J., Gao L., Peng X., Meng Y., Li W.;
RT   "ZNF268, a novel kruppel-like zinc finger protein, is implicated in early
RT   human liver development.";
RL   Int. J. Mol. Med. 14:971-975(2004).
RN   [9]
RP   INDUCTION BY ATF4.
RX   PubMed=16787922; DOI=10.1074/jbc.m602753200;
RA   Guo M.X., Wang D., Shao H.J., Qiu H.L., Xue L., Zhao Z.Z., Zhu C.G.,
RA   Shi Y.B., Li W.X.;
RT   "Transcription of human zinc finger ZNF268 gene requires an intragenic
RT   promoter element.";
RL   J. Biol. Chem. 281:24623-24636(2006).
RN   [10]
RP   ALTERNATIVE SPLICING, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=16735226;
RA   Sun C., Zhao Z.Z., Gao L., Sun Y., Shao H.J., Li W.X.;
RT   "Cloning and characterization of two novel alternatively spliced
RT   transcripts of ZNF268.";
RL   Yi Chuan 28:513-517(2006).
RN   [11]
RP   INDUCTION BY UPF1.
RX   PubMed=18774934; DOI=10.1134/s0006297908080051;
RA   Zhu C., Zhao Z., Guo M., Shao H., Qiu H., Wang D., Xu J., Xue L., Li W.;
RT   "The mammalian gene ZNF268 is regulated by hUpf1.";
RL   Biochemistry (Mosc.) 73:881-885(2008).
RN   [12]
RP   INDUCTION BY HTLV-1 TAX.
RX   PubMed=18375384; DOI=10.1074/jbc.m706426200;
RA   Wang D., Guo M.X., Hu H.M., Zhao Z.Z., Qiu H.L., Shao H.J., Zhu C.G.,
RA   Xue L., Shi Y.B., Li W.X.;
RT   "Human T-cell leukemia virus type 1 oncoprotein tax represses ZNF268
RT   expression through the cAMP-responsive element-binding protein/activating
RT   transcription factor pathway.";
RL   J. Biol. Chem. 283:16299-16308(2008).
RN   [13]
RP   FUNCTION, ALTERNATIVE SPLICING (ISOFORMS 1 AND 2), SUBCELLULAR LOCATION,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18677094;
RA   Chun J.N., Song I.S., Kang D.H., Song H.J., Kim H.I., Seo J., Suh J.W.,
RA   Lee K.J., Lee K.J., Kim J., Kang S.W.;
RT   "A splice variant of the C(2)H(2)-type zinc finger protein, ZNF268s,
RT   regulates NF-kappaB activation by TNF-alpha.";
RL   Mol. Cells 26:175-180(2008).
RN   [14]
RP   FUNCTION (ISOFORMS 1 AND 2), INTERACTION WITH CHUK AND IKBKB, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=23091055; DOI=10.1074/jbc.m112.399923;
RA   Wang W., Guo M., Hu L., Cai J., Zeng Y., Luo J., Shu Z., Li W., Huang Z.;
RT   "The zinc finger protein ZNF268 is overexpressed in human cervical cancer
RT   and contributes to tumorigenesis via enhancing NF-kappaB signaling.";
RL   J. Biol. Chem. 287:42856-42866(2012).
RN   [15]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=22235304; DOI=10.1371/journal.pone.0029518;
RA   Zeng Y., Wang W., Ma J., Wang X., Guo M., Li W.;
RT   "Knockdown of ZNF268, which is transcriptionally downregulated by GATA-1,
RT   promotes proliferation of K562 cells.";
RL   PLoS ONE 7:E29518-E29518(2012).
RN   [16]
RP   INTERACTION WITH TRIM28, SUBCELLULAR LOCATION (ISOFORMS 1 AND 2), AND
RP   MUTAGENESIS OF ASP-85; VAL-86; VAL-88; PHE-90; GLU-93; GLU-94 AND TRP-95.
RX   PubMed=23665872; DOI=10.1007/s00018-013-1359-4;
RA   Wang W., Cai J., Wu Y., Hu L., Chen Z., Hu J., Chen Z., Li W., Guo M.,
RA   Huang Z.;
RT   "Novel activity of KRAB domain that functions to reinforce nuclear
RT   localization of KRAB-containing zinc finger proteins by interacting with
RT   KAP1.";
RL   Cell. Mol. Life Sci. 70:3947-3958(2013).
RN   [17]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=23946776; DOI=10.3892/ol.2013.1318;
RA   Hu L., Wang W., Cai J., Luo J., Huang Y., Xiong S., Li W., Guo M.;
RT   "Aberrant expression of ZNF268 alters the growth and migration of ovarian
RT   cancer cells.";
RL   Oncol. Lett. 6:49-54(2013).
RN   [18]
RP   STRUCTURE BY NMR OF 272-947.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the C2H2 type zinc finger region of human zinc
RT   finger protein 268.";
RL   Submitted (OCT-2007) to the PDB data bank.
CC   -!- FUNCTION: [Isoform 1]: Acts as a transcriptional repressor. Inhibits
CC       erythroid differentiation and tumor cell proliferation. Plays a role
CC       during ovarian cancer development and progression.
CC   -!- FUNCTION: [Isoform 2]: Contributes to cervical carcinogenesis in part
CC       through the TNF-alpha-induced NF-kappa-B signaling pathway by
CC       interacting with the I-kappa-B-kinase (IKK) core complex.
CC   -!- SUBUNIT: Interacts (via the KRAB domain) with TRIM28 (via the RBCC
CC       domain); the interaction increases ZNF268 nuclear localization
CC       activity. Isoform 2 interacts with CHUK and IKBKB; the interaction is
CC       further increased in a TNF-alpha-dependent manner.
CC       {ECO:0000269|PubMed:23091055, ECO:0000269|PubMed:23665872}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus
CC       {ECO:0000269|PubMed:23665872}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus
CC       {ECO:0000269|PubMed:23665872}. Cytoplasm {ECO:0000269|PubMed:23665872}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=1; Synonyms=ZNF268a, KW-4 variant-1;
CC         IsoId=Q14587-1; Sequence=Displayed;
CC       Name=2; Synonyms=ZNF268s, KW-4 variant-2;
CC         IsoId=Q14587-2; Sequence=VSP_006909;
CC       Name=3; Synonyms=ZNF268c;
CC         IsoId=Q14587-3; Sequence=VSP_053461, VSP_053471;
CC       Name=4; Synonyms=ZNF268d;
CC         IsoId=Q14587-4; Sequence=VSP_053462, VSP_053467;
CC       Name=5; Synonyms=ZNF268e;
CC         IsoId=Q14587-6; Sequence=VSP_053466, VSP_053468;
CC       Name=6; Synonyms=ZNF268f;
CC         IsoId=Q14587-7; Sequence=VSP_053464, VSP_053465;
CC       Name=7; Synonyms=ZNF268g;
CC         IsoId=Q14587-8; Sequence=VSP_053463, VSP_053469, VSP_053470;
CC   -!- TISSUE SPECIFICITY: Overexpressed in ovarian cancer tissues compared to
CC       normal ovarian tissues. Isoform 1 and isoform 2 are expressed in
CC       squamous epithelium tissues. Isoform 2 is overexpressed in squamous
CC       cervical cancer (at protein level). Expressed in blood cells. Isoform 1
CC       is expressed in pancreas, lung, skeletal muscle, heart, placenta,
CC       liver, kidney and brain. Isoform 2 expressed in chronic lymphocytic
CC       leukemia (CLL) and several tumor cell lines. Isoform 3 is expressed in
CC       several tumor cells. Isoform 5 is expressed in fetal liver and several
CC       tumor cells. Isoform 6 is weakly expressed in brain, lung amd small
CC       intestin and in several tumor cells. Isoform 7 is expressed in fetal
CC       liver and several tumor cells. {ECO:0000269|PubMed:12200376,
CC       ECO:0000269|PubMed:16735226, ECO:0000269|PubMed:16865230,
CC       ECO:0000269|PubMed:18949428, ECO:0000269|PubMed:23091055,
CC       ECO:0000269|PubMed:23946776}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in fetal liver from 5 weeks until 4
CC       months but drastically reduced by 6 months and became non-detectable by
CC       7 months. Expressed in hematopoietic stem cells in 3 weeks and 5 weeks
CC       (at protein level). Expressed in fetal liver.
CC       {ECO:0000269|PubMed:15547661, ECO:0000269|PubMed:16735226}.
CC   -!- INDUCTION: Down-regulated during erythroid differentiation by GATA1.
CC       Down-regulated by HTLV-1 Tax through the CREB/ATF pathway. Up-regulated
CC       by the regulator of nonsense transcript UPF1. Up-regulated by the
CC       cyclic AMP-dependent transcription factor ATF4.
CC       {ECO:0000269|PubMed:16787922, ECO:0000269|PubMed:18375384,
CC       ECO:0000269|PubMed:18774934, ECO:0000269|PubMed:22235304}.
CC   -!- DOMAIN: The KRAB domain functions to reinforce the nuclear localization
CC       of isoform 1 in addition to its transcription repression activity.
CC   -!- SIMILARITY: Belongs to the krueppel C2H2-type zinc-finger protein
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF317549; AAG59817.1; -; mRNA.
DR   EMBL; AF385187; AAK69307.1; -; mRNA.
DR   EMBL; AF432217; AAL99923.1; -; mRNA.
DR   EMBL; AC026785; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; DQ057356; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; DQ057357; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; DQ057358; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; DQ057359; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; DQ057360; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X78926; CAA55526.1; -; mRNA.
DR   CCDS; CCDS45012.1; -. [Q14587-1]
DR   CCDS; CCDS53853.1; -. [Q14587-4]
DR   CCDS; CCDS59240.1; -. [Q14587-6]
DR   PIR; S47071; S47071.
DR   RefSeq; NP_001159353.1; NM_001165881.2. [Q14587-1]
DR   RefSeq; NP_001159355.1; NM_001165883.1. [Q14587-6]
DR   RefSeq; NP_001159356.2; NM_001165884.2.
DR   RefSeq; NP_001159357.1; NM_001165885.1.
DR   RefSeq; NP_001159358.1; NM_001165886.1.
DR   RefSeq; NP_001159359.1; NM_001165887.1.
DR   RefSeq; NP_003406.1; NM_003415.2. [Q14587-1]
DR   RefSeq; NP_694422.2; NM_152943.2.
DR   PDB; 2EL4; NMR; -; A=663-695.
DR   PDB; 2EL5; NMR; -; A=749-777.
DR   PDB; 2EL6; NMR; -; A=831-863.
DR   PDB; 2EM1; NMR; -; A=637-667.
DR   PDB; 2EMV; NMR; -; A=859-889.
DR   PDB; 2EMW; NMR; -; A=301-331.
DR   PDB; 2EMX; NMR; -; A=273-303.
DR   PDB; 2EMY; NMR; -; A=551-583.
DR   PDB; 2EN0; NMR; -; A=385-413.
DR   PDB; 2EN6; NMR; -; A=887-919.
DR   PDB; 2EN7; NMR; -; A=495-525.
DR   PDB; 2EOF; NMR; -; A=411-441.
DR   PDB; 2EOG; NMR; -; A=693-723.
DR   PDB; 2EOI; NMR; -; A=329-359.
DR   PDB; 2EOJ; NMR; -; A=355-385.
DR   PDB; 2EOK; NMR; -; A=441-469.
DR   PDB; 2EOL; NMR; -; A=581-609.
DR   PDB; 2EOP; NMR; -; A=719-751.
DR   PDB; 2EPV; NMR; -; A=803-833.
DR   PDB; 2EPW; NMR; -; A=915-947.
DR   PDB; 2EPY; NMR; -; A=525-553.
DR   PDB; 2YTF; NMR; -; A=607-639.
DR   PDB; 2YTQ; NMR; -; A=775-807.
DR   PDBsum; 2EL4; -.
DR   PDBsum; 2EL5; -.
DR   PDBsum; 2EL6; -.
DR   PDBsum; 2EM1; -.
DR   PDBsum; 2EMV; -.
DR   PDBsum; 2EMW; -.
DR   PDBsum; 2EMX; -.
DR   PDBsum; 2EMY; -.
DR   PDBsum; 2EN0; -.
DR   PDBsum; 2EN6; -.
DR   PDBsum; 2EN7; -.
DR   PDBsum; 2EOF; -.
DR   PDBsum; 2EOG; -.
DR   PDBsum; 2EOI; -.
DR   PDBsum; 2EOJ; -.
DR   PDBsum; 2EOK; -.
DR   PDBsum; 2EOL; -.
DR   PDBsum; 2EOP; -.
DR   PDBsum; 2EPV; -.
DR   PDBsum; 2EPW; -.
DR   PDBsum; 2EPY; -.
DR   PDBsum; 2YTF; -.
DR   PDBsum; 2YTQ; -.
DR   AlphaFoldDB; Q14587; -.
DR   SMR; Q14587; -.
DR   BioGRID; 116010; 13.
DR   IntAct; Q14587; 1.
DR   STRING; 9606.ENSP00000444412; -.
DR   iPTMnet; Q14587; -.
DR   PhosphoSitePlus; Q14587; -.
DR   BioMuta; ZNF268; -.
DR   DMDM; 19863363; -.
DR   EPD; Q14587; -.
DR   jPOST; Q14587; -.
DR   MassIVE; Q14587; -.
DR   MaxQB; Q14587; -.
DR   PaxDb; Q14587; -.
DR   PeptideAtlas; Q14587; -.
DR   ProteomicsDB; 60060; -. [Q14587-1]
DR   ProteomicsDB; 60061; -. [Q14587-2]
DR   Antibodypedia; 834; 184 antibodies from 19 providers.
DR   DNASU; 10795; -.
DR   Ensembl; ENST00000228289.9; ENSP00000228289.5; ENSG00000090612.22. [Q14587-1]
DR   Ensembl; ENST00000536435.7; ENSP00000444412.3; ENSG00000090612.22. [Q14587-1]
DR   Ensembl; ENST00000539248.6; ENSP00000467781.1; ENSG00000090612.22. [Q14587-6]
DR   Ensembl; ENST00000588312.2; ENSP00000466622.1; ENSG00000090612.22. [Q14587-7]
DR   GeneID; 10795; -.
DR   KEGG; hsa:10795; -.
DR   MANE-Select; ENST00000536435.7; ENSP00000444412.3; NM_003415.3; NP_003406.1.
DR   UCSC; uc010tbw.3; human. [Q14587-1]
DR   AGR; HGNC:13061; -.
DR   CTD; 10795; -.
DR   DisGeNET; 10795; -.
DR   GeneCards; ZNF268; -.
DR   HGNC; HGNC:13061; ZNF268.
DR   HPA; ENSG00000090612; Low tissue specificity.
DR   MIM; 604753; gene.
DR   neXtProt; NX_Q14587; -.
DR   OpenTargets; ENSG00000090612; -.
DR   PharmGKB; PA37639; -.
DR   VEuPathDB; HostDB:ENSG00000090612; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   GeneTree; ENSGT00940000163459; -.
DR   HOGENOM; CLU_002678_17_1_1; -.
DR   InParanoid; Q14587; -.
DR   OMA; MKPYVCS; -.
DR   OrthoDB; 4637982at2759; -.
DR   PhylomeDB; Q14587; -.
DR   PathwayCommons; Q14587; -.
DR   Reactome; R-HSA-212436; Generic Transcription Pathway.
DR   SignaLink; Q14587; -.
DR   SIGNOR; Q14587; -.
DR   BioGRID-ORCS; 10795; 12 hits in 1181 CRISPR screens.
DR   ChiTaRS; ZNF268; human.
DR   EvolutionaryTrace; Q14587; -.
DR   GeneWiki; ZNF268; -.
DR   GenomeRNAi; 10795; -.
DR   Pharos; Q14587; Tbio.
DR   PRO; PR:Q14587; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q14587; protein.
DR   Bgee; ENSG00000090612; Expressed in adrenal tissue and 191 other tissues.
DR   ExpressionAtlas; Q14587; baseline and differential.
DR   Genevisible; Q14587; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; NAS:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; NAS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:1901224; P:positive regulation of NIK/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0090073; P:positive regulation of protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; NAS:UniProtKB.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0043497; P:regulation of protein heterodimerization activity; IDA:UniProtKB.
DR   CDD; cd07765; KRAB_A-box; 1.
DR   Gene3D; 6.10.140.140; -; 1.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 24.
DR   InterPro; IPR001909; KRAB.
DR   InterPro; IPR036051; KRAB_dom_sf.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR47772; ZINC FINGER PROTEIN 200; 1.
DR   PANTHER; PTHR47772:SF2; ZINC FINGER PROTEIN 436; 1.
DR   Pfam; PF01352; KRAB; 1.
DR   Pfam; PF00096; zf-C2H2; 20.
DR   SMART; SM00349; KRAB; 1.
DR   SMART; SM00355; ZnF_C2H2; 24.
DR   SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 12.
DR   SUPFAM; SSF109640; KRAB domain (Kruppel-associated box); 1.
DR   PROSITE; PS50805; KRAB; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 24.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 24.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Differentiation;
KW   DNA-binding; Metal-binding; Nucleus; Reference proteome; Repeat; Repressor;
KW   Transcription; Transcription regulation; Zinc; Zinc-finger.
FT   CHAIN           1..947
FT                   /note="Zinc finger protein 268"
FT                   /id="PRO_0000047495"
FT   DOMAIN          81..152
FT                   /note="KRAB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00119"
FT   ZN_FING         276..298
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         304..326
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         332..354
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         360..382
FT                   /note="C2H2-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         388..410
FT                   /note="C2H2-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         416..438
FT                   /note="C2H2-type 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         444..466
FT                   /note="C2H2-type 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         472..494
FT                   /note="C2H2-type 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         500..522
FT                   /note="C2H2-type 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         528..550
FT                   /note="C2H2-type 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         556..578
FT                   /note="C2H2-type 11"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         584..606
FT                   /note="C2H2-type 12"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         612..634
FT                   /note="C2H2-type 13"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         640..662
FT                   /note="C2H2-type 14"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         668..690
FT                   /note="C2H2-type 15"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         696..718
FT                   /note="C2H2-type 16"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         724..746
FT                   /note="C2H2-type 17"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         752..774
FT                   /note="C2H2-type 18"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         780..802
FT                   /note="C2H2-type 19"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         808..830
FT                   /note="C2H2-type 20"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         836..858
FT                   /note="C2H2-type 21"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         864..886
FT                   /note="C2H2-type 22"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         892..914
FT                   /note="C2H2-type 23"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         920..942
FT                   /note="C2H2-type 24"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   VAR_SEQ         1..161
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11311945,
FT                   ECO:0000303|PubMed:12200376"
FT                   /id="VSP_006909"
FT   VAR_SEQ         1..140
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:16865230,
FT                   ECO:0000303|PubMed:18949428"
FT                   /id="VSP_053461"
FT   VAR_SEQ         12..99
FT                   /note="VPPLQERNSSWDRIRKLQGQESILGQGTPGLQPLPGTPRQKQKSRRIEKVLE
FT                   WLFISQEQPKITKSWGPLSFMDVFVDFTWEEWQLLD -> GTNTPNLISSSSWNKEKSC
FT                   VWCRPKFQIRPVQTQSGKLMILWIGIRKIKTSWEVWQKALNALHLENYVFLVQSIFQDK
FT                   NLINVARMERV (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:16865230,
FT                   ECO:0000303|PubMed:18949428"
FT                   /id="VSP_053462"
FT   VAR_SEQ         12..78
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:16865230,
FT                   ECO:0000303|PubMed:18949428"
FT                   /id="VSP_053463"
FT   VAR_SEQ         12..44
FT                   /note="VPPLQERNSSWDRIRKLQGQESILGQGTPGLQP -> GTNTPNLISSSSWNK
FT                   EKSCVWCRPKFQIRPVQF (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:16865230,
FT                   ECO:0000303|PubMed:18949428"
FT                   /id="VSP_053464"
FT   VAR_SEQ         45..947
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:16865230,
FT                   ECO:0000303|PubMed:18949428"
FT                   /id="VSP_053465"
FT   VAR_SEQ         79..135
FT                   /note="GPLSFMDVFVDFTWEEWQLLDPAQKCLYRSVMLENYSNLVSLGYQHTKPDII
FT                   FKLEQ -> TQSGKLMILWIGIRKIKTSWEVRQKALNALHLENYVFLVQSIFQDKNLIN
FT                   VARMERV (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:16865230,
FT                   ECO:0000303|PubMed:18949428"
FT                   /id="VSP_053466"
FT   VAR_SEQ         100..947
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:16865230,
FT                   ECO:0000303|PubMed:18949428"
FT                   /id="VSP_053467"
FT   VAR_SEQ         136..947
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:16865230,
FT                   ECO:0000303|PubMed:18949428"
FT                   /id="VSP_053468"
FT   VAR_SEQ         153..183
FT                   /note="NTVWKIDDLMDWHQENKDKLGSTAKSFECTT -> ILKAGKSKAKVLAGLVS
FT                   GEGPLCASKMTPCC (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:16865230,
FT                   ECO:0000303|PubMed:18949428"
FT                   /id="VSP_053469"
FT   VAR_SEQ         184..947
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:16865230,
FT                   ECO:0000303|PubMed:18949428"
FT                   /id="VSP_053470"
FT   VAR_SEQ         222..947
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:16865230,
FT                   ECO:0000303|PubMed:18949428"
FT                   /id="VSP_053471"
FT   VARIANT         175
FT                   /note="T -> M (in dbSNP:rs7975069)"
FT                   /id="VAR_033562"
FT   MUTAGEN         85
FT                   /note="D->A: Strongly reduces nuclear localization and
FT                   interaction with TRIM28; when associated with A-86."
FT                   /evidence="ECO:0000269|PubMed:23665872"
FT   MUTAGEN         86
FT                   /note="V->A: Reduces nuclear localization. Strongly reduces
FT                   nuclear localization and interaction with TRIM28; when
FT                   associated with A-85."
FT                   /evidence="ECO:0000269|PubMed:23665872"
FT   MUTAGEN         88
FT                   /note="V->A: Reduces nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:23665872"
FT   MUTAGEN         90
FT                   /note="F->A: Reduces nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:23665872"
FT   MUTAGEN         93
FT                   /note="E->A: Reduces nuclear localization. Strongly reduces
FT                   nuclear localization; when associated with A-94 and A-95."
FT                   /evidence="ECO:0000269|PubMed:23665872"
FT   MUTAGEN         94
FT                   /note="E->A: Reduces nuclear localization. Inhibits nuclear
FT                   localization; when associated with A-93 and A-95."
FT                   /evidence="ECO:0000269|PubMed:23665872"
FT   MUTAGEN         95
FT                   /note="W->A: Reduces nuclear localization. Inhibits nuclear
FT                   localization; when associated with A-93 and A-94."
FT                   /evidence="ECO:0000269|PubMed:23665872"
FT   CONFLICT        323
FT                   /note="Q -> P (in Ref. 2; AAL99923)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        335..336
FT                   /note="SE -> IN (in Ref. 2; AAL99923)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        340
FT                   /note="T -> A (in Ref. 2; AAL99923)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        344
FT                   /note="H -> Q (in Ref. 2; AAL99923)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        363
FT                   /note="C -> D (in Ref. 2; AAL99923)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        409
FT                   /note="I -> T (in Ref. 2; AAL99923)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        860
FT                   /note="R -> T (in Ref. 2; AAL99923 and 6; CAA55526)"
FT                   /evidence="ECO:0000305"
FT   STRAND          279..282
FT                   /evidence="ECO:0007829|PDB:2EMX"
FT   STRAND          284..287
FT                   /evidence="ECO:0007829|PDB:2EMX"
FT   HELIX           288..298
FT                   /evidence="ECO:0007829|PDB:2EMX"
FT   STRAND          304..306
FT                   /evidence="ECO:0007829|PDB:2EMW"
FT   TURN            307..310
FT                   /evidence="ECO:0007829|PDB:2EMW"
FT   STRAND          311..315
FT                   /evidence="ECO:0007829|PDB:2EMW"
FT   HELIX           316..323
FT                   /evidence="ECO:0007829|PDB:2EMW"
FT   TURN            324..326
FT                   /evidence="ECO:0007829|PDB:2EMW"
FT   STRAND          335..337
FT                   /evidence="ECO:0007829|PDB:2EOI"
FT   STRAND          340..343
FT                   /evidence="ECO:0007829|PDB:2EOI"
FT   HELIX           344..354
FT                   /evidence="ECO:0007829|PDB:2EOI"
FT   TURN            363..366
FT                   /evidence="ECO:0007829|PDB:2EOJ"
FT   HELIX           372..379
FT                   /evidence="ECO:0007829|PDB:2EOJ"
FT   STRAND          382..385
FT                   /evidence="ECO:0007829|PDB:2EOJ"
FT   STRAND          391..393
FT                   /evidence="ECO:0007829|PDB:2EN0"
FT   STRAND          396..399
FT                   /evidence="ECO:0007829|PDB:2EN0"
FT   HELIX           400..411
FT                   /evidence="ECO:0007829|PDB:2EN0"
FT   STRAND          415..417
FT                   /evidence="ECO:0007829|PDB:2EOF"
FT   TURN            419..421
FT                   /evidence="ECO:0007829|PDB:2EOF"
FT   STRAND          424..426
FT                   /evidence="ECO:0007829|PDB:2EOF"
FT   HELIX           428..437
FT                   /evidence="ECO:0007829|PDB:2EOF"
FT   TURN            438..440
FT                   /evidence="ECO:0007829|PDB:2EOF"
FT   STRAND          443..445
FT                   /evidence="ECO:0007829|PDB:2EOK"
FT   STRAND          447..449
FT                   /evidence="ECO:0007829|PDB:2EOK"
FT   STRAND          452..455
FT                   /evidence="ECO:0007829|PDB:2EOK"
FT   HELIX           456..465
FT                   /evidence="ECO:0007829|PDB:2EOK"
FT   TURN            466..468
FT                   /evidence="ECO:0007829|PDB:2EOK"
FT   STRAND          495..500
FT                   /evidence="ECO:0007829|PDB:2EN7"
FT   TURN            503..505
FT                   /evidence="ECO:0007829|PDB:2EN7"
FT   HELIX           512..519
FT                   /evidence="ECO:0007829|PDB:2EN7"
FT   TURN            520..522
FT                   /evidence="ECO:0007829|PDB:2EN7"
FT   STRAND          527..529
FT                   /evidence="ECO:0007829|PDB:2EPY"
FT   STRAND          531..533
FT                   /evidence="ECO:0007829|PDB:2EPY"
FT   STRAND          536..539
FT                   /evidence="ECO:0007829|PDB:2EPY"
FT   HELIX           540..547
FT                   /evidence="ECO:0007829|PDB:2EPY"
FT   TURN            548..550
FT                   /evidence="ECO:0007829|PDB:2EPY"
FT   STRAND          559..561
FT                   /evidence="ECO:0007829|PDB:2EMY"
FT   STRAND          564..567
FT                   /evidence="ECO:0007829|PDB:2EMY"
FT   HELIX           568..578
FT                   /evidence="ECO:0007829|PDB:2EMY"
FT   TURN            587..589
FT                   /evidence="ECO:0007829|PDB:2EOL"
FT   STRAND          592..596
FT                   /evidence="ECO:0007829|PDB:2EOL"
FT   HELIX           597..606
FT                   /evidence="ECO:0007829|PDB:2EOL"
FT   STRAND          611..613
FT                   /evidence="ECO:0007829|PDB:2YTF"
FT   STRAND          615..617
FT                   /evidence="ECO:0007829|PDB:2YTF"
FT   STRAND          620..623
FT                   /evidence="ECO:0007829|PDB:2YTF"
FT   HELIX           624..632
FT                   /evidence="ECO:0007829|PDB:2YTF"
FT   STRAND          639..642
FT                   /evidence="ECO:0007829|PDB:2EM1"
FT   TURN            643..646
FT                   /evidence="ECO:0007829|PDB:2EM1"
FT   STRAND          647..651
FT                   /evidence="ECO:0007829|PDB:2EM1"
FT   HELIX           652..659
FT                   /evidence="ECO:0007829|PDB:2EM1"
FT   TURN            660..662
FT                   /evidence="ECO:0007829|PDB:2EM1"
FT   STRAND          667..669
FT                   /evidence="ECO:0007829|PDB:2EL4"
FT   STRAND          671..674
FT                   /evidence="ECO:0007829|PDB:2EL4"
FT   STRAND          676..679
FT                   /evidence="ECO:0007829|PDB:2EL4"
FT   HELIX           680..686
FT                   /evidence="ECO:0007829|PDB:2EL4"
FT   HELIX           687..689
FT                   /evidence="ECO:0007829|PDB:2EL4"
FT   STRAND          690..692
FT                   /evidence="ECO:0007829|PDB:2EL4"
FT   STRAND          699..701
FT                   /evidence="ECO:0007829|PDB:2EOG"
FT   HELIX           708..719
FT                   /evidence="ECO:0007829|PDB:2EOG"
FT   TURN            727..729
FT                   /evidence="ECO:0007829|PDB:2EOP"
FT   HELIX           736..743
FT                   /evidence="ECO:0007829|PDB:2EOP"
FT   TURN            744..748
FT                   /evidence="ECO:0007829|PDB:2EOP"
FT   STRAND          751..753
FT                   /evidence="ECO:0007829|PDB:2EL5"
FT   STRAND          755..757
FT                   /evidence="ECO:0007829|PDB:2EL5"
FT   STRAND          760..763
FT                   /evidence="ECO:0007829|PDB:2EL5"
FT   HELIX           764..771
FT                   /evidence="ECO:0007829|PDB:2EL5"
FT   HELIX           772..774
FT                   /evidence="ECO:0007829|PDB:2EL5"
FT   STRAND          783..785
FT                   /evidence="ECO:0007829|PDB:2YTQ"
FT   HELIX           792..799
FT                   /evidence="ECO:0007829|PDB:2YTQ"
FT   TURN            800..802
FT                   /evidence="ECO:0007829|PDB:2YTQ"
FT   STRAND          807..809
FT                   /evidence="ECO:0007829|PDB:2EPV"
FT   STRAND          811..813
FT                   /evidence="ECO:0007829|PDB:2EPV"
FT   STRAND          816..819
FT                   /evidence="ECO:0007829|PDB:2EPV"
FT   HELIX           820..827
FT                   /evidence="ECO:0007829|PDB:2EPV"
FT   HELIX           828..830
FT                   /evidence="ECO:0007829|PDB:2EPV"
FT   STRAND          835..837
FT                   /evidence="ECO:0007829|PDB:2EL6"
FT   STRAND          839..842
FT                   /evidence="ECO:0007829|PDB:2EL6"
FT   STRAND          844..847
FT                   /evidence="ECO:0007829|PDB:2EL6"
FT   HELIX           848..855
FT                   /evidence="ECO:0007829|PDB:2EL6"
FT   HELIX           856..858
FT                   /evidence="ECO:0007829|PDB:2EL6"
FT   STRAND          862..865
FT                   /evidence="ECO:0007829|PDB:2EMV"
FT   STRAND          867..869
FT                   /evidence="ECO:0007829|PDB:2EMV"
FT   STRAND          872..875
FT                   /evidence="ECO:0007829|PDB:2EMV"
FT   HELIX           876..886
FT                   /evidence="ECO:0007829|PDB:2EMV"
FT   TURN            895..897
FT                   /evidence="ECO:0007829|PDB:2EN6"
FT   STRAND          900..903
FT                   /evidence="ECO:0007829|PDB:2EN6"
FT   HELIX           904..914
FT                   /evidence="ECO:0007829|PDB:2EN6"
FT   STRAND          919..921
FT                   /evidence="ECO:0007829|PDB:2EPW"
FT   STRAND          923..925
FT                   /evidence="ECO:0007829|PDB:2EPW"
FT   STRAND          928..932
FT                   /evidence="ECO:0007829|PDB:2EPW"
FT   HELIX           933..941
FT                   /evidence="ECO:0007829|PDB:2EPW"
SQ   SEQUENCE   947 AA;  108374 MW;  AC78F4824F4BE1A0 CRC64;
     MATRVRTASI WVPPLQERNS SWDRIRKLQG QESILGQGTP GLQPLPGTPR QKQKSRRIEK
     VLEWLFISQE QPKITKSWGP LSFMDVFVDF TWEEWQLLDP AQKCLYRSVM LENYSNLVSL
     GYQHTKPDII FKLEQGEELC MVQAQVPNQT CPNTVWKIDD LMDWHQENKD KLGSTAKSFE
     CTTFGKLCLL STKYLSRQKP HKCGTHGKSL KYIDFTSDYA RNNPNGFQVH GKSFFHSKHE
     QTVIGIKYCE SIESGKTVNK KSQLMCQQMY MGEKPFGCSC CEKAFSSKSY LLVHQQTHAE
     EKPYGCNECG KDFSSKSYLI VHQRIHTGEK LHECSECRKT FSFHSQLVIH QRIHTGENPY
     ECCECGKVFS RKDQLVSHQK THSGQKPYVC NECGKAFGLK SQLIIHERIH TGEKPYECNE
     CQKAFNTKSN LMVHQRTHTG EKPYVCSDCG KAFTFKSQLI VHQGIHTGVK PYGCIQCGKG
     FSLKSQLIVH QRSHTGMKPY VCNECGKAFR SKSYLIIHTR THTGEKLHEC NNCGKAFSFK
     SQLIIHQRIH TGENPYECHE CGKAFSRKYQ LISHQRTHAG EKPYECTDCG KAFGLKSQLI
     IHQRTHTGEK PFECSECQKA FNTKSNLIVH QRTHTGEKPY SCNECGKAFT FKSQLIVHKG
     VHTGVKPYGC SQCAKTFSLK SQLIVHQRSH TGVKPYGCSE CGKAFRSKSY LIIHMRTHTG
     EKPHECRECG KSFSFNSQLI VHQRIHTGEN PYECSECGKA FNRKDQLISH QRTHAGEKPY
     GCSECGKAFS SKSYLIIHMR THSGEKPYEC NECGKAFIWK SLLIVHERTH AGVNPYKCSQ
     CEKSFSGKLR LLVHQRMHTR EKPYECSECG KAFIRNSQLI VHQRTHSGEK PYGCNECGKT
     FSQKSILSAH QRTHTGEKPC KCTECGKAFC WKSQLIMHQR THVDDKH
//
